Dr Jean-Pascal Machiels (Cliniques Universitaires Saint-Luc, Brussels, Belgium) joins touchONCOLOGY to discuss clinical trial highlights in head and neck cancer presented at EMSO 2022.
Questions:
- What are the hot topics and highlights in head and neck cancers from ESMO 2022?
Disclosures: Jean-Pascal Machiels is an Advisory board member or speaker with honoraria (managed by my Institution) for Pfizer, Roche, Astra/Zeneca, Bayer, Innate, Merck Serono, Boerhinger, BMS, Novartis, Janssen, Incyte, Cue Biopharma, ALX Oncology, iTEOS, eTheRNA, NEKTAR, F-Star. He receives travel expenses from Amgen, BMS, Pfizer, MSD, and Gilead; is on the data safety monitoring board with honoraria for Psioxus; has an institutional conflict of interest (Funding to institution for research support) with all companies above; has an uncompensated advisory role at MSD; and is the EORTC investigator and study coordinator, and H & N group Chair.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.
